在COVID-19患者中失调的白皮质素代谢
Halef Okan Doğan1, Mahir Budak2, Kübra Doğan3
1Department of Biochemistry, School of Medicine, Sivas Cumhuriyet University, Turkey.
Japanese journal of infectious diseases
|January 3, 2024
概括
COVID-19 改变了白血素代谢,使患者的5-氧酶 (5-LO) 水平降低. 氨基白血受体1 (CYSLTR1) mRNA表达随着疾病严重程度的增加而增加,这表明它是潜在的COVID-19严重程度生物标志物.
科学领域:
- 生物化学 生化学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- COVID-19是一种具有复杂病理生理学的呼吸系统疾病.
- 叶洛克代谢在炎症反应中起作用.
- 了解COVID-19中的代谢变化对于治疗策略至关重要.
研究的目的:
- 为了研究COVID-19患者的白血代谢.
- 为了比较健康对照组,非重症监护室 (非ICU) 患者和重症监护室 (ICU) 患者之间的代谢概况.
- 为了确定COVID-19严重程度的潜在生物标志物.
主要方法:
- 在180名参与者 (60对照组,60非ICU,60ICU) 中测量了5-lipoxygenase (5-LO),5-LO激活蛋白 (ALOX5AP) 和cysteinyl leukotriene (CYSLT) 的血清水平.
- 分析了5-LO,ALOX5AP和cysteinyl leukotriene受体1 (CYSLTR1) 的mRNA表达水平.
- 两组之间进行了统计比较.
主要成果:
- 与对照组相比,非ICU和ICU患者均表现出较低的血清5-LO和mRNA表达.
- 强症监护室患者的5-LO水平和mRNA表达明显低于非强症监护室患者.
- 在ICU组中,CYSLTR1mRNA表达最高,其次是非ICU组,对照组中最低.
- 对照组的CYSLT水平高于非ICU和ICU患者.
- 与对照组相比,CYSLTR1的表达在COVID-19患者中升高,与疾病严重程度相关.
结论:
- 在COVID-19患者中,子代谢发生了显著的变化.
- 减少的5-LO活性和增加的CYSLTR1表达与COVID-19的严重程度有关.
- CYSLTR1 mRNA表达可能成为预测COVID-19严重程度的有希望的生物标志物.
- 选择性白血受体阻断剂可能是COVID-19的潜在治疗选择.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
Asthma: Pathogenesis and Management
405
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
405
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Disorders of Leukocytes
958
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
958
Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445


